Cancer statistics, 2023
- PMID: 36633525
- DOI: 10.3322/caac.21763
Cancer statistics, 2023
Abstract
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries and mortality data collected by the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases; otherwise, however, incidence trends were more favorable in men compared to women. For example, lung cancer in women decreased at one half the pace of men (1.1% vs. 2.6% annually) from 2015 through 2019, and breast and uterine corpus cancers continued to increase, as did liver cancer and melanoma, both of which stabilized in men aged 50 years and older and declined in younger men. However, a 65% drop in cervical cancer incidence during 2012 through 2019 among women in their early 20s, the first cohort to receive the human papillomavirus vaccine, foreshadows steep reductions in the burden of human papillomavirus-associated cancers, the majority of which occur in women. Despite the pandemic, and in contrast with other leading causes of death, the cancer death rate continued to decline from 2019 to 2020 (by 1.5%), contributing to a 33% overall reduction since 1991 and an estimated 3.8 million deaths averted. This progress increasingly reflects advances in treatment, which are particularly evident in the rapid declines in mortality (approximately 2% annually during 2016 through 2020) for leukemia, melanoma, and kidney cancer, despite stable/increasing incidence, and accelerated declines for lung cancer. In summary, although cancer mortality rates continue to decline, future progress may be attenuated by rising incidence for breast, prostate, and uterine corpus cancers, which also happen to have the largest racial disparities in mortality.
Keywords: cancer cases; cancer statistics; death rates; incidence; mortality.
© 2023 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.
Similar articles
-
Cancer statistics, 2020.CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8. CA Cancer J Clin. 2020. PMID: 31912902
-
Cancer statistics, 2024.CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17. CA Cancer J Clin. 2024. PMID: 38230766
-
Annual report to the nation on the status of cancer, part 1: National cancer statistics.Cancer. 2022 Dec 15;128(24):4251-4284. doi: 10.1002/cncr.34479. Epub 2022 Oct 27. Cancer. 2022. PMID: 36301149 Free PMC article.
-
Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99. doi: 10.1093/jnci/djg040. J Natl Cancer Inst. 2003. PMID: 12953083 Review.
-
Cancer statistics, 2004.CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29. doi: 10.3322/canjclin.54.1.8. CA Cancer J Clin. 2004. PMID: 14974761 Review.
Cited by
-
Identifying causal relationships between 35 blood and urine biomarkers and urologic cancers: MR-meta combined with Bayesian colocalization Mendelian randomization analysis.Discov Oncol. 2024 Nov 4;15(1):617. doi: 10.1007/s12672-024-01493-0. Discov Oncol. 2024. PMID: 39495393 Free PMC article.
-
Oncolytic virotherapy against lung cancer: key receptors and signaling pathways of viral entry.Front Immunol. 2024 Oct 4;15:1473288. doi: 10.3389/fimmu.2024.1473288. eCollection 2024. Front Immunol. 2024. PMID: 39430750 Free PMC article. Review.
-
Prevalence and associated risk factors of prostate cancer among a large Chinese population.Sci Rep. 2024 Nov 1;14(1):26338. doi: 10.1038/s41598-024-77863-z. Sci Rep. 2024. PMID: 39487298 Free PMC article.
-
Prostate cancer lesions in transition zone exhibit a higher propensity for pathological upgrading in radical prostatectomy.World J Urol. 2024 Oct 30;42(1):608. doi: 10.1007/s00345-024-05294-6. World J Urol. 2024. PMID: 39476187 Free PMC article.
-
Precision medicine in metastatic colorectal cancer: targeting KRAS G12C mutation.Transl Gastroenterol Hepatol. 2024 Sep 12;9:53. doi: 10.21037/tgh-24-28. eCollection 2024. Transl Gastroenterol Hepatol. 2024. PMID: 39503041 Free PMC article. No abstract available.
References
REFERENCES
-
- Ghoshal S, Rigney G, Cheng D, et al. Institutional surgical response and associated volume trends throughout the COVID-19 pandemic and postvaccination recovery period. JAMA Netw Open. 2022;5(8):e2227443. doi:10.1001/jamanetworkopen.2022.27443
-
- Yabroff KR, Wu XC, Negoita S, et al. Association of the COVID-19 pandemic with patterns of statewide cancer services. J Natl Cancer Inst. 2022;114(6):907-909.
-
- Chen R, Aschmann HE, Chen YH, et al. Racial and ethnic disparities in estimated excess mortality from external causes in the US, March to December 2020. JAMA Intern Med. 2022;182(7):776-778. doi:10.1001/jamainternmed.2022.1461
-
- Woolf SH, Chapman DA, Sabo RT, Zimmerman EB. Excess deaths from COVID-19 and other causes in the US, March 1, 2020, to January 2, 2021. JAMA. 2021;325(17):1786. doi:10.1001/jama.2021.5199
-
- Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER Research Data with Delay-Adjustment, 8 Registries, Malignant Only (1975-2019), based on the November 2021 submission. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2022.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical